TABLE 1.
Screen | Compound | Growth restoration (% of untreated control) |
---|---|---|
C. albicans, 5 μM fluconazole | Untreated | 100 |
Fluconazole alone | 0 | |
Fendiline hydrochloride | 132 | |
Methiothepin maleate | 122 | |
Hexetidine | 115 | |
Prenylamine lactate | 83 | |
Mometasone furoate | 121 | |
Etofenamate | 102 | |
Dimethisoquin hydrochloride | 58 | |
Pinaverium bromide | 131 | |
Halofantrine hydrochloride | 119 | |
Penbutolol sulfate | 109 | |
Thiethylperazine dimalate | 70 | |
Toltrazuril | 63 | |
Aripiprazole | 122 | |
C. glabrata, 100 μM fluconazole | Untreated | 100 |
Fluconazole alone | 0 | |
Parthenolide | 61 | |
Estramustine | 58 |
The Prestwick collection, containing a variety of FDA-approved drugs, was screened with each compound at a final concentration of 5 μM to identify those which restore the growth of either C. albicans or C. glabrata in the presence of inhibitory concentrations of fluconazole. Hits were defined as compounds that restored fungal growth to at least 50% of level seen with the untreated control wells.